Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 498 across all filing types
Latest filing 2026-05-30 Report Publication Anno…
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 90% confidence The document is an intimation letter under SEBI Regulation 47 sent to the BSE/NSE, stating that newspaper extracts of the audited standalone and consolidated financial results have been published and are enclosed. It does not itself contain the full financial statements but merely announces and attaches the publication of results (newspaper cuttings). Thus, by the “menu vs meal” rule it is an announcement of a report’s publication, fitting the Report Publication Announcement (RPA) category rather than the report itself.
2026-05-30 English
Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026.
Interim / Quarterly Report Classification · 84% confidence The document is an official stock‐exchange filing under SEBI Listing Regulations containing “Extracts of the newspaper publications … relating to the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March 2026,” followed by detailed tables of audited financial results for multiple companies covering quarterly and year‐end periods. It contains substantive financial data (actual income, profit, EPS, etc.) for interim periods (quarters) rather than a full narrative annual report or mere notice. Therefore it best fits the “Interim / Quarterly Report (IR)” category. FY 2026
2026-05-30 English
Appointment
Board/Management Information Classification · 92% confidence The document is an intimation under SEBI Listing Regulations announcing the appointment of a new Chief Executive Officer. It provides details on the change in senior management (Regulation 30 disclosure). This falls squarely under announcements of board or management changes (Board/Management Information).
2026-05-29 English
Outcome of Board Meeting
Regulatory Filings Classification · 85% confidence The document is a formal notification to stock exchanges under SEBI Listing Regulations of the “Outcome of Board Meeting.” It covers approval of audited financial results (with auditor’s report in annexure), an update on a previously proposed object‐clause alteration, and the appointment of the CEO. It is a regulatory announcement of board decisions and includes audit reports via annexures rather than embedding full financial tables or running commentary/analysis. It does not present a full interim or annual report itself (it refers to annexures for details), nor is it a short press‐style earnings release or investor presentation. There is no specific category for “board meeting outcomes,” so it falls into the fallback “Regulatory Filings” category for miscellaneous compliance disclosures to the exchange.
2026-05-29 English
Annual Secretarial Compliance Report of the financial year ended 31st March 2026
Regulatory Filings Classification · 92% confidence The document is an Annual Secretarial Compliance Report prepared by a practicing Company Secretary under Regulation 24A of SEBI (LODR) Regulations. It is a statutory compliance certificate attesting to the company’s adherence to listing regulations, filed with the stock exchanges. It contains no financial statements or management analysis; rather, it is a regulatory filing / officer certification. Under the Classification Rules, such attestations fall under Regulatory Filings (RNS).
2026-05-29 English
Appointment of Chief Executive Officer.
Board/Management Information Classification · 95% confidence The document is a formal stock exchange filing under SEBI Listing Regulations announcing the appointment of a new Chief Executive Officer at Brooks Laboratories. It provides details required under Regulation 30 and is clearly a management change notice. This falls squarely under Board/Management Information (MANG).
2026-05-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.